Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Enzon Consolidates Manufacturing Operations | Contract Pharma
Breaking News

Enzon Consolidates Manufacturing Operations

Enzon Pharmaceuticals, Inc. plans to consolidate its manufacturing operations in Indianapolis from its South Plainfield, NJ facility. The closing of the NJ facility is expected to impact approximately 50 employees. The company plans to assist them in their transition, and expects total restructuring charges of between $8 and $10 million associated with the transition, as well as a write-off of an estimated $8 million related to the leased facility in 2008.

This consolidation is part of the company’s efforts to streamline operations to optimize efficiencies. According to the company, it will continue to focus investment on key priorities including developing innovative oncology therapies and advancing its clinical pipeline. The consolidation is not expected to affect Enzon’s contract manufacturing operations.

“Enzon continues to focus on building a premier oncology business, developing and commercializing important medicines for patients with life-threatening diseases,” said Jeffrey H. Buchalter, chairman and chief executive officer of Enzon. “As we continue to drive towards delivering on this goal, we have to make difficult decisions such as this one. We express our gratitude to the employees affected by this change for their numerous contributions to Enzon over the years.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters